1. Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study 
William J. Sandborn, Stefan Schreiber, Stephen B. Hanauer, Jean–Frédéric Colombel, Ralph Bloomfield, Gary R. Lichtenstein 
Clinical Gastroenterology and Hepatology 
Volume 8, Issue 8, Pages e1 (August 2010)
DOI: /j.cgh
Copyright © 2010 AGA Institute Terms and Conditions

2. Figure 1 Study design. czp, certolizumab pegol.
Clinical Gastroenterology and Hepatology 2010 8, e1DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

3. Figure 2
(A) Response rates (reduction from week 0 in HBI score of ≥3) and (B) remission rates (HBI score of ≤4) in PRECiSE 4 (intention-to-treat population).
Clinical Gastroenterology and Hepatology 2010 8, e1DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

4. Figure 3
Geometric mean plasma concentration of certolizumab pegol (95% confidence interval) in patients with or without anti–certolizumab pegol antibodies. (A) Group A (drug interruption group), (B) group B (continuous maintenance group). czp, certolizumab pegol.
Clinical Gastroenterology and Hepatology 2010 8, e1DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions